Literature DB >> 18361776

Correctors promote folding of the CFTR in the endoplasmic reticulum.

Tip W Loo1, M Claire Bartlett, David M Clarke.   

Abstract

Cystic fibrosis (CF) is most commonly caused by deletion of a residue (DeltaF508) in the CFTR (cystic fibrosis transmembrane conductance regulator) protein. The misfolded mutant protein is retained in the ER (endoplasmic reticulum) and is not trafficked to the cell surface (misprocessed mutant). Corrector molecules such as corr-2b or corr-4a are small molecules that increase the amount of functional CFTR at the cell surface. Correctors may function by stabilizing CFTR at the cell surface or by promoting folding in the ER. To test whether correctors promoted folding of CFTR in the ER, we constructed double-cysteine CFTR mutants that would be retained in the ER and only undergo cross-linking when the protein folds into a native structure. The mature form, but not the immature forms, of M348C(TM6)/T1142C(TM12) (where TM is transmembrane segment), T351C(TM6)/T1142C(TM12) and W356C(TM6)/W1145C(TM12) mutants were efficiently cross-linked. Mutations to the COPII (coatamer protein II) exit motif (Y(563)KDAD(567)) were then made in the cross-linkable cysteine mutants to prevent the mutant proteins from leaving the ER. Membranes were prepared from the mutants expressed in the absence or presence of correctors and subjected to disulfide cross-linking analysis. The presence of correctors promoted folding of the mutants as the efficiency of cross-linking increased from approx. 2-5% to 22-35%. The results suggest that correctors interact with CFTR in the ER to promote folding of the protein into a native structure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18361776     DOI: 10.1042/BJ20071690

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  26 in total

1.  Cell surface rescue of kidney anion exchanger 1 mutants by disruption of chaperone interactions.

Authors:  Sian T Patterson; Reinhart A F Reithmeier
Journal:  J Biol Chem       Date:  2010-07-13       Impact factor: 5.157

2.  Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures.

Authors:  Deborah M Cholon; Wanda K O'Neal; Scott H Randell; John R Riordan; Martina Gentzsch
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-12-11       Impact factor: 5.464

Review 3.  Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies.

Authors:  C N Belcher; N Vij
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

4.  Low temperature and chemical rescue affect molecular proximity of DeltaF508-cystic fibrosis transmembrane conductance regulator (CFTR) and epithelial sodium channel (ENaC).

Authors:  Yawar J Qadri; Estelle Cormet-Boyaka; Arun K Rooj; William Lee; Vladimir Parpura; Cathy M Fuller; Bakhrom K Berdiev
Journal:  J Biol Chem       Date:  2012-03-22       Impact factor: 5.157

5.  Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.

Authors:  Puay-Wah Phuan; Baoxue Yang; John M Knapp; Alex B Wood; Gergely L Lukacs; Mark J Kurth; A S Verkman
Journal:  Mol Pharmacol       Date:  2011-07-05       Impact factor: 4.436

6.  Hsp70 and Hsp90 multichaperone complexes sequentially regulate thiazide-sensitive cotransporter endoplasmic reticulum-associated degradation and biogenesis.

Authors:  Bridget F Donnelly; Patrick G Needham; Avin C Snyder; Ankita Roy; Shaheen Khadem; Jeffrey L Brodsky; Arohan R Subramanya
Journal:  J Biol Chem       Date:  2013-03-12       Impact factor: 5.157

Review 7.  Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators.

Authors:  Ania C Muntau; João Leandro; Michael Staudigl; Felix Mayer; Søren W Gersting
Journal:  J Inherit Metab Dis       Date:  2014-04-01       Impact factor: 4.982

Review 8.  Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies.

Authors:  James L Kreindler
Journal:  Pharmacol Ther       Date:  2009-11-10       Impact factor: 12.310

9.  The V510D suppressor mutation stabilizes DeltaF508-CFTR at the cell surface.

Authors:  Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  Biochemistry       Date:  2010-08-03       Impact factor: 3.162

10.  Mechanisms for rescue of correctable folding defects in CFTRDelta F508.

Authors:  Diane E Grove; Meredith F N Rosser; Hong Yu Ren; Anjaparavanda P Naren; Douglas M Cyr
Journal:  Mol Biol Cell       Date:  2009-07-22       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.